erlotinib hydrochloride has been researched along with rivaroxaban in 1 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (rivaroxaban) | Trials (rivaroxaban) | Recent Studies (post-2010) (rivaroxaban) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 4,741 | 569 | 4,357 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | rivaroxaban (IC50) |
|---|---|---|---|
| Coagulation factor X | Homo sapiens (human) | 0.0038 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chan, ECY; Cheong, EJY; Chin, SY; Ng, DZW; Wang, Z | 1 |
1 other study(ies) available for erlotinib hydrochloride and rivaroxaban
| Article | Year |
|---|---|
Application of a physiologically based pharmacokinetic model of rivaroxaban to prospective simulations of drug-drug-disease interactions with protein kinase inhibitors in cancer-associated venous thromboembolism.
Topics: Cytochrome P-450 CYP3A; Drug Interactions; Erlotinib Hydrochloride; Humans; Ketoconazole; Models, Biological; Neoplasms; Prospective Studies; Protein Kinase Inhibitors; Rivaroxaban; Venous Thromboembolism | 2022 |